Vericel: Q1 Earnings Insights
Vericel (NASDAQ:VCEL) reported its Q1 earnings results on Wednesday, May 4, 2022 at 08:00 AM.
Here's what investors need to know about the announcement.
Earnings Scheduled For May 4, 2022
Companies Reporting Before The Bell
• Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.
Vericel Q1 2022 Earnings Conference Call On May 4, 2022 At 08:30 AM ET
Vericel (NASDAQ:VCEL) will host a conference call at 08:30 AM ET on May 4, 2022, to discuss Q1 2022 earnings results.
How to Attend Vericel (VCEL) Conference Call
Follow this link to access the live webcast.
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries.
The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks That Hit 52-Week Lows On Thursday
During Thursday's morning trading, 152 companies set new 52-week lows.
Jim Cramer Believes Penn National Is A Winner, Likes Vericel
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he likes Penn National Gaming, Inc. (NASDAQ: PENN), calling the stock as a winner.
Truist Securities Maintains Buy on Vericel, Lowers Price Target to $52
Truist Securities maintains Vericel (NASDAQ:VCEL) with a Buy and lowers the price target from $55 to $52.